Marker Therapeutics to Present at the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Marker Therapeutics (NASDAQ:MRKR), a leader in immuno-oncology, announced that CEO Peter L. Hoang will present at the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020, from 1:40 to 2:20 p.m. ET. The event will showcase the company's innovative T cell-based therapies targeting hematological malignancies and solid tumors. Live webcasts of the presentation will be available on the Investors section of their website and can be replayed afterward.
- None.
- None.
HOUSTON, Sept. 17, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its President and Chief Executive Officer, Peter L. Hoang, will present at the upcoming Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 22, 2020.
CONFERENCE DETAILS
Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Tuesday, Sept. 22, 2020
Time: 1:40-2:20 p.m. ET
Live webcasts of the presentation will be accessible from the Investors section of the company's website at markertherapeutics.com and will be available for replay following the event.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.
View original content to download multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-the-virtual-oppenheimer-fall-healthcare-life-sciences--medtech-summit-301132782.html
SOURCE Marker Therapeutics, Inc.
FAQ
When will Marker Therapeutics present at the Oppenheimer Summit?
What time is the Marker Therapeutics presentation at the summit?
Who is presenting for Marker Therapeutics?
Where can I watch the Marker Therapeutics presentation?
What is the focus of Marker Therapeutics' presentation?
